Healthcare services company Chemed Corporation (NYSE: CHE) announced better-than-expected revenue in Q3 2026, with sales up 10.6% year on year to $690.9 million. Its non-GAAP profit of $6.75 per share was 4.9% above analysts’ consensus estimates.

Is now the time to buy CHE? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Chemed’s third quarter saw positive market reaction, with results surpassing Wall Street’s revenue and non-GAAP profit expectations. Management attributed the strong performance to robust admissions growth and cost control at VITAS, as well as revenue gains across both residential and commercial segments at Roto-Rooter. CEO Kevin McNamara noted, “The combination of ADC growth and cost containment, particularly with respect to central support costs, drove significant revenue and income growth at VITAS during the third quarter.”

Looking ahead, Chemed’s outlook is shaped by the ongoing integration of recent Roto-Rooter franchise acquisitions, continued focus on operational efficiency, and stable demand for VITAS’s hospice services. Management stated that cost control and patient mix will remain priorities, and that integrating lower-margin acquired businesses may weigh on near-term margins. CFO Michael Witzeman emphasized, "Acquiring territories with significant and growing population characteristics is the right thing to do for the long term at Roto-Rooter."

Key insights from management’s remarks

Management cited volume growth at VITAS and commercial momentum at Roto-Rooter as central to the quarter’s performance, while persistent marketing and fuel cost pressures moderated short-term margins.

• VITAS admissions recovery: VITAS’s patient admissions rose across all care settings, with hospital-directed admissions up 5.7% and non-hospital sources increasing more than 8% in several categories. This broad-based growth reflects a stable referral mix and tailwinds from enhanced access and compliance programs.
• Cost control at VITAS: The hospice segment maintained high EBITDA margins through disciplined cost management, including reductions in selling, general, and administrative expenses and efficient staffing practices using electronic tools. Management highlighted that full-time equivalents were below budget for most of the quarter, helping to offset wage and inflationary pressures.
• Roto-Rooter commercial expansion: The commercial business manager program continued to outperform, driving commercial revenue up approximately 10.9% in branches with dedicated managers. This focus has been crucial as paid lead costs have risen and free internet-generated leads have declined.
• Acquisitions reshape Roto-Rooter: The reacquisition of franchise territories, particularly in Texas and California, contributed to top-line growth but introduced acquired businesses with structurally lower EBITDA margins. Management expects a 12–18 month timeline to fully integrate these territories and improve their profitability.
• Marketing expenses as a headwind: Roto-Rooter faced higher marketing spending due to an increased share of paid leads and intensifying digital competition, especially from Google’s changing search landscape. Management noted that over half of all leads now come through paid channels, raising customer acquisition costs and impacting margins.

Drivers of future performance

Chemed’s guidance is anchored in continued organic growth at VITAS, ongoing integration of newly acquired Roto-Rooter territories, and margin management amid persistent cost headwinds.

• Margin pressure from acquisitions: As the company integrates recently acquired Roto-Rooter franchises, management expects overall segment margins to remain below historical averages in the near term. These new businesses operate at lower profitability initially and require operational improvements to align with Chemed’s standards.
• Marketing and cost inflation risks: Roto-Rooter’s reliance on paid digital marketing channels is expected to continue driving up customer acquisition costs, while fuel inflation remains a challenge. Management is monitoring these headwinds closely, aiming to offset them through higher job pricing and operational leverage as scale grows.
• VITAS stability and labor environment: Management anticipates steady demand in hospice care, supported by strong referral relationships and minimal hiring difficulties. While wage inflation is present, Chemed’s cost containment strategies and technology-driven staffing tools are expected to help maintain margins in the healthcare segment.

Catalysts in upcoming quarters

In the coming quarters, our analysts will be watching (1) the pace at which newly acquired Roto-Rooter territories improve their profitability and integrate into the broader branch network, (2) the sustainability of admissions growth and margin management at VITAS, and (3) Chemed’s ability to contain rising marketing and fuel costs at Roto-Rooter. Updates on digital lead generation initiatives and further acquisition activity will also be key indicators of execution.

Chemed currently trades at $531.22, up from $508.80 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).

Now could be the perfect time to invest in these stocks

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.